First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Saved in:
| Title: | First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. |
|---|---|
| Authors: | Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Xu B; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China., Dumbrava EE; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Rodon JA; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Raghav K; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Ajani JA; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Mott F; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Fan Y; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China., Fan J; Clinical Department, TransThera Sciences (US), Inc., Gaithersburg, MA, USA., Peng P; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Wang H; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Ni S; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Sun C; Clinical Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Qiang X; Biology Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Levin WJ; Clinical Department, CRC Oncology, San Diego, CA, USA., Ngo B; Clinical Department, CRC Oncology, San Diego, CA, USA., Ru QC; Clinical Department, CRC Oncology, San Diego, CA, USA., Wu F; Project Management Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China.; Drug Metabolism and Pharmacokinetics Department, TransThera Sciences (Nanjing), Inc., Nanjing, People's Republic of China., Javle MM; Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | The oncologist [Oncologist] 2024 Apr 04; Vol. 29 (4), pp. e514-e525. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
